Osteoporosis International

, Volume 19, Issue 3, pp 349–356 | Cite as

Adherence to alendronate in male veterans

  • K. E. Hansen
  • E. D. Swenson
  • B. Baltz
  • A. A. Schuna
  • A. N. Jones
  • M. E. Elliott
Original Article

Abstract

Summary

In one Veterans Affairs’ medical center, alendronate non-adherence was more likely in male veterans who smoke or report side effects, and less likely in men undergoing bone densitometry during therapy. Providers urgently need programs to increase adherence to osteoporosis medications. Initial programs should target patients with risk factors for non-adherence.

Introduction

Adherence to osteoporosis therapy in men is unknown. We hypothesized that ca. 50% of men at one center would be adherent to alendronate and one or more patient-specific factors would associate with adherence.

Methods

We conducted a retrospective chart review study of male veterans to determine the rates and predictors of alendronate adherence over two years. We excluded women, men who received primary care elsewhere and those who took alendronate for indications other than low bone mass. We defined adherence as a medication possession ratio ≥80% in the first 24 months of therapy.

Results

Adherence in the first 12 and 24 months of therapy was 59% and 54%, respectively. In multivariate analyses, non-adherence was more likely in men using tobacco (OR 2.08, 95% CI 1.13, 3.84, p = 0.02) and reporting side effects (OR 2.06, 95% CI 1.14, 3.73, p = 0.02) and less likely in men undergoing bone density during therapy (OR 0.49, 95% CI 0.26, 0.90, p = 0.02).

Conclusions

Alendronate non-adherence is more likely in male veterans who smoke or report side effects, and less likely in men having bone densitometry during therapy. Providers urgently need programs to increase adherence to osteoporosis medications. Initial programs should target patients with risk factors for non-adherence.

Keywords

Adherence Alendronate Medication possession ratio Men Osteoporosis Treatment 

References

  1. 1.
    Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81:646–656PubMedGoogle Scholar
  2. 2.
    (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795Google Scholar
  3. 3.
    (2003) Physician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation: Washington, DCGoogle Scholar
  4. 4.
    Binkley N, Krueger D (2002) Osteoporosis in men. WMJ 101:28–32PubMedGoogle Scholar
  5. 5.
    Compston J (2001) Secondary causes of osteoporosis in men. Calcif Tissue Int 69:193–195PubMedCrossRefGoogle Scholar
  6. 6.
    Kelepouris N, Harper KD, Gannon F et al (1995) Severe osteoporosis in men. Ann Intern Med 123:452–460PubMedGoogle Scholar
  7. 7.
    Riggs BL, Khosla S, Melton LJ 3rd (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763–773PubMedCrossRefGoogle Scholar
  8. 8.
    Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610PubMedCrossRefGoogle Scholar
  9. 9.
    Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211PubMedCrossRefGoogle Scholar
  10. 10.
    Wallach S, Cohen S, Reid DM et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285PubMedCrossRefGoogle Scholar
  11. 11.
    Finkelstein JS, Hayes A, Hunzelman JL et al (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226PubMedCrossRefGoogle Scholar
  12. 12.
    Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17PubMedCrossRefGoogle Scholar
  13. 13.
    Badamgarav E, Fitzpatrick LA (2006) A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc 81:1009–1012PubMedGoogle Scholar
  14. 14.
    Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRefGoogle Scholar
  15. 15.
    McCombs JS, Thiebaud P, McLaughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRefGoogle Scholar
  16. 16.
    Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedGoogle Scholar
  17. 17.
    Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRefGoogle Scholar
  18. 18.
    Weycker D, Macarios D, Edelsberg J et al (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652PubMedCrossRefGoogle Scholar
  19. 19.
    Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861PubMedGoogle Scholar
  20. 20.
    Solomon DH, Avorn J, Katz JN et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419PubMedCrossRefGoogle Scholar
  21. 21.
    Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968PubMedCrossRefGoogle Scholar
  22. 22.
    Papaioannou A, Ioannidis G, Adachi JD et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808–813PubMedCrossRefGoogle Scholar
  23. 23.
    Curtis, JR, Westfall AO, Allison JJ et al (2006) Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 17:1268–1274PubMedCrossRefGoogle Scholar
  24. 24.
    Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905PubMedCrossRefGoogle Scholar
  25. 25.
    Rossini M, Bianchi G, Di Munno O et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921PubMedCrossRefGoogle Scholar
  26. 26.
    Gold DT, Alexander IM, Ettinger MP (2006) How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother 40:1143–1150PubMedCrossRefGoogle Scholar
  27. 27.
    Lo JC, Pressman AR, Omar MA et al (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922–928PubMedCrossRefGoogle Scholar
  28. 28.
    Downey TW, Foltz SH, Boccuzzi SJ et al (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99:570–575PubMedCrossRefGoogle Scholar
  29. 29.
    Ensrud KE, Barrett-Connor EL, Schwartz A et al (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19:1259–1269PubMedCrossRefGoogle Scholar
  30. 30.
    Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRefGoogle Scholar
  31. 31.
    Fisher L, Belle GV (1993) Biostatistics: a methodology for the health sciences. Wiley, New YorkGoogle Scholar
  32. 32.
    Vik SA, Hogan DB, Patten SB et al (2006) Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs Aging 23:345–356PubMedCrossRefGoogle Scholar
  33. 33.
    Barr RG, Somers SC, Speizer FE et al (2002) Patient factors and medication guideline adherence among older women with asthma. Arch Intern Med 162:1761–1768PubMedCrossRefGoogle Scholar
  34. 34.
    Lavigne M, Rocher I, Steensma C et al (2006) The impact of smoking on adherence to treatment for latent tuberculosis infection. BMC Public Health 6:66PubMedCrossRefGoogle Scholar
  35. 35.
    Law MR, Hackshaw AK (1997) A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 315:841–846PubMedGoogle Scholar
  36. 36.
    Solomon DH, Avorn J (2003) Pharmacoepidemiology and rheumatic diseases: 2001–2002. Curr Opin Rheumatol 15:122–126PubMedCrossRefGoogle Scholar
  37. 37.
    Morris AB, Li J, Kroenke K et al (2006) Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy 26:483–492PubMedCrossRefGoogle Scholar
  38. 38.
    Benner JS, Glynn RJ, Mogun H et al (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455–461PubMedCrossRefGoogle Scholar
  39. 39.
    Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638–1644PubMedCrossRefGoogle Scholar
  40. 40.
    Miller PD, Woodson G, Licata AA et al (2000) Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 22:1433–1442PubMedCrossRefGoogle Scholar
  41. 41.
    Compston JE, Seeman E (2006) Compliance with osteoporosis therapy is the weakest link. Lancet 368:973–974PubMedCrossRefGoogle Scholar
  42. 42.
    Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRefGoogle Scholar
  43. 43.
    Wu JY, Leung WY, Chang S et al (2006) Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ 333:522PubMedCrossRefGoogle Scholar
  44. 44.
    Raynor DK, Booth TG, Blenkinsopp A (1993) Effects of computer generated reminder charts on patients’ compliance with drug regimens. BMJ 306:1158–1161PubMedCrossRefGoogle Scholar
  45. 45.
    Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2007

Authors and Affiliations

  • K. E. Hansen
    • 1
    • 2
    • 5
  • E. D. Swenson
    • 1
  • B. Baltz
    • 3
  • A. A. Schuna
    • 4
  • A. N. Jones
    • 1
    • 2
  • M. E. Elliott
    • 3
    • 4
  1. 1.University of Wisconsin School of Medicine and Public HealthMadisonUSA
  2. 2.University of Wisconsin Osteoporosis Clinical Center & Research ProgramMadisonUSA
  3. 3.University of Wisconsin School of PharmacyMadisonUSA
  4. 4.William S. Middleton Veterans Affairs Medical CenterMadisonUSA
  5. 5.Department of MedicineUW School of Medicine and Public HealthMadisonUSA

Personalised recommendations